Tag: pharmaceuticals

  • Private-Public Consortium to Share IP on Tropical Diseases

    The World Intellectual Property Organization (WIPO) has formed a partnership with pharmaceutical companies and BIO Ventures for Global Health (BVGH) to share intellectual property and expertise to develop treatments for neglected tropical diseases, malaria, and tuberculosis. The partnership includes international and national research and public health agencies, as well as research universities and non-government organizations.…

  • Blood Pressure Meds at Bed Time Reduce Heart Disease Risk

    Researchers at University of Vigo in Spain have found that taking blood pressure medicines at bed time appears to reduce risk of heart disease as well as keep blood pressure under control. They describe their research online this week in the Journal of the American Society of Nephrology (paid subscription required). Hypertension affects about one-third…

  • Novartis to Cut Jobs in U.S., Switzerland; Add Jobs in Asia

    In its third-quarter financial report released today, the Swiss pharmaceutical company Novartis AG said it would cut some 2,000 jobs in Switzerland and the U.S., but add 700 jobs in China and India. The cuts were announced at the same time the company said it recorded gains in third quarter sales of 12 percent and…

  • Contract Awarded to Test Nerve-Agent Protection Drug

    An NIH program to develop countermeasures against chemical weapons has awarded a contract to a University of Colorado researcher to evaluate a commercial drug’s ability to protect against nerve agents. The $736,000 contract from NIH’s Countermeasures Against Chemical Threats (CounterACT) Research Network to Manisha Patel (pictured left), at University of Colorado’s School of Pharmacy in…

  • U.S. Venture Investments Up in Q3, Science Companies Mixed

    Dow Jones VentureSource reports that venture capital (VC) investment in the U.S. rose in the third quarter of 2011 compared to 2010, including the number and size of deals and investment volume. Among science-based companies, medical device and energy companies gained in investment deals and volume. Among biotech and pharmaceutical companies, the number of deals…

  • Johns Hopkins, Eisai to Collaborate on New Brain Drugs

    Johns Hopkins University (JHU) in Baltimore and Eisai, a pharmaceutical company in Tokyo, will collaborate on research for discovery of drugs for brain conditions such as schizophrenia, pain, brain tumors and Alzheimer’s disease. The partnership will be part of the NeuroTranslational Program in JHU’s Brain Science Institute. The Brain Science Institute researches questions about brain…

  • Pharma, Technology Lead Worldwide Corporate R&D Rebound

    Research and development spending by the largest 1,400 corporate R&D spenders worldwide increased by more than 4 percent to €465 billion ($US 630 billion) in 2010, reversing a nearly 2 percent decline in 2009. The data are compiled in the European Commission’s EU Industrial R&D Investment Scoreboard, released today. Pharmaceuticals/biotechnology, technology hardware, and automotive companies…

  • Harvard Program to Apply Systems Approach to Drug Discovery

    Harvard Medical School is launching an Initiative in Systems Pharmacology, to develop what it calls a comprehensive strategy to transform drug discovery. The program aims to reverse the slowdown in the development of new therapies and involve a range of disciplines and methods outside the usual collection of life scientists and clinicians. Marc Kirschner, who…

  • NIH Awards Infectious Disease Therapy Contracts

    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded contracts totaling $37.5 million to five companies to develop therapies for diseases caused by multiple types of bacteria or viruses. The five-year orders, with a potential total value of $150 million, cover research to extend promising drug candidates…

  • Survey: VCs Pulling Back from Biopharma, Devices Companies

    A survey of venture capital (VC) companies investing in health care enterprises says they have shifted funding away from businesses that develop drugs and medical devices toward less regulated services and information technology firms. The survey, conducted by the National Venture Capital Association (NVCA) from July to September 2011, covers 156 of its members with…